Home > Publications Database > Early-Life Adversity Predicts Markers of Aging-Related Neuroinflammation, Neurodegeneration, and Cognitive Impairment in Women. > print

001     277508
005     20250323000956.0
024 7 _ |a 10.1002/ana.27161
|2 doi
024 7 _ |a pmid:39786167
|2 pmid
024 7 _ |a pmc:PMC11889533
|2 pmc
024 7 _ |a 0364-5134
|2 ISSN
024 7 _ |a 1531-8249
|2 ISSN
024 7 _ |a altmetric:172919099
|2 altmetric
037 _ _ |a DZNE-2025-00419
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Fleck, Lara
|0 0000-0001-9436-5008
|b 0
245 _ _ |a Early-Life Adversity Predicts Markers of Aging-Related Neuroinflammation, Neurodegeneration, and Cognitive Impairment in Women.
260 _ _ |a Hoboken, NJ
|c 2025
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1742378538_22981
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Despite the overwhelming evidence for profound and longstanding effects of early-life stress (ELS) on inflammation, brain structure, and molecular aging, its impact on human brain aging and risk for neurodegenerative disease is poorly understood. We examined the impact of ELS severity in interaction with age on blood-based markers of neuroinflammation and neurodegeneration, brain volumes, and cognitive function in middle-aged women.We recruited 179 women (aged 30-60 years) with and without ELS exposure before the onset of puberty. Using Simoa technology, we assessed blood-based markers of neuroinflammation and neurodegeneration, including serum concentrations of glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL). We further obtained T1-weighted and T2-weighted magnetic resonance images to assess brain volumes and we assessed cognitive performance sensitive to early impairments associated with the development of dementia, using the Cambridge Neuropsychological Automated Test Battery. We used generalized additive models to examine nonlinear interaction effects of ELS severity and age on these outcomes.Analyses revealed significant nonlinear interaction effects of ELS severity and age on NfL and GFAP serum concentrations, total and subcortical gray matter volume loss, increased third ventricular volume, and cognitive impairment.These findings suggest that ELS profoundly exacerbates peripheral, neurostructural, and cognitive markers of brain aging. Our results are critical for the development of novel early prevention strategies that target the impact of developmental stress on the brain to mitigate aging-related neurological diseases. ANN NEUROL 2025;97:642-656.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Neurofilament Proteins
|2 NLM Chemicals
650 _ 7 |a Glial Fibrillary Acidic Protein
|2 NLM Chemicals
650 _ 7 |a neurofilament protein L
|2 NLM Chemicals
650 _ 7 |a GFAP protein, human
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: blood
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: diagnostic imaging
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Aging: pathology
|2 MeSH
650 _ 2 |a Neurodegenerative Diseases: blood
|2 MeSH
650 _ 2 |a Neurodegenerative Diseases: diagnostic imaging
|2 MeSH
650 _ 2 |a Biomarkers: blood
|2 MeSH
650 _ 2 |a Adverse Childhood Experiences
|2 MeSH
650 _ 2 |a Neurofilament Proteins: blood
|2 MeSH
650 _ 2 |a Neuroinflammatory Diseases: diagnostic imaging
|2 MeSH
650 _ 2 |a Neuroinflammatory Diseases: blood
|2 MeSH
650 _ 2 |a Neuroinflammatory Diseases: pathology
|2 MeSH
650 _ 2 |a Glial Fibrillary Acidic Protein: blood
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging
|2 MeSH
650 _ 2 |a Brain: diagnostic imaging
|2 MeSH
650 _ 2 |a Brain: pathology
|2 MeSH
700 1 _ |a Buss, Claudia
|b 1
700 1 _ |a Bauer, Martin
|b 2
700 1 _ |a Stein, Maike
|b 3
700 1 _ |a Mekle, Ralf
|b 4
700 1 _ |a Kock, Lena
|b 5
700 1 _ |a Klawitter, Heiko
|b 6
700 1 _ |a Godara, Malvika
|b 7
700 1 _ |a Ramler, Judith
|b 8
700 1 _ |a Entringer, Sonja
|b 9
700 1 _ |a Endres, Matthias
|0 P:(DE-2719)2811033
|b 10
700 1 _ |a Heim, Christine
|0 0000-0002-6580-6326
|b 11
773 _ _ |a 10.1002/ana.27161
|g Vol. 97, no. 4, p. 642 - 656
|0 PERI:(DE-600)2037912-2
|n 4
|p 642 - 656
|t Annals of neurology
|v 97
|y 2025
|x 0364-5134
856 4 _ |u https://pub.dzne.de/record/277508/files/DZNE-2025-00419%20SUP.docx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/277508/files/DZNE-2025-00419.pdf
856 4 _ |u https://pub.dzne.de/record/277508/files/DZNE-2025-00419%20SUP.doc
856 4 _ |u https://pub.dzne.de/record/277508/files/DZNE-2025-00419%20SUP.odt
856 4 _ |u https://pub.dzne.de/record/277508/files/DZNE-2025-00419%20SUP.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/277508/files/DZNE-2025-00419.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:277508
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2811033
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-18
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ANN NEUROL : 2022
|d 2024-12-18
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ANN NEUROL : 2022
|d 2024-12-18
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-18
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-18
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-18
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-18
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-18
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-18
920 1 _ |0 I:(DE-2719)1811005
|k AG Endres
|l Interdisciplinary Dementia Research
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1811005
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21